What is the current Night Blindness Treatment market size?

The Night Blindness Treatment market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Night Blindness Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Night Blindness Treatment market?

Key drivers include rising prevalence of night blindness and increasing awareness of treatment options.

What are the major challenges facing the Night Blindness Treatment market?

Challenges include high treatment costs and limited access to healthcare in developing regions.

Which regions are leading the Night Blindness Treatment market?

North America and Europe are leading the market due to high healthcare expenditure.

Who are the top companies in the Night Blindness Treatment market?

Top companies include Novartis, Pfizer, and Roche, which offer a range of treatment options.

What future opportunities exist in the Night Blindness Treatment market?

Future opportunities include emerging markets and innovative treatments, such as gene therapy.

How is technology impacting the Night Blindness Treatment market?

Technology is improving diagnosis and treatment outcomes, with advances in genetic testing and gene editing.

What is the regulatory landscape for the Night Blindness Treatment market?

The regulatory landscape is evolving, with increasing focus on safety and efficacy of new treatments.

What is the future outlook for the Night Blindness Treatment market?

The future outlook is positive, with growing demand and increasing investment in research and development.

Night Blindness Treatment Expansion Opportunities & Forecast Analysis 2033

Night Blindness Treatment by Type (/> Vitamin AD Drops, Vitamin AD Softgels, Vitamin A Capsule), by Application (/> Clinic, Hospital), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Night Blindness Treatment Market Size | CAGR 6.2 Forecast 2033

Night Blindness Treatment Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Night Blindness Treatment Market Overview

The Night Blindness Treatment market refers to the industry focused on addressing vision impairment in low-light conditions. As the Night Blindness Treatment market size is expected to reach $1.4 billion by 2026, the growth outlook and market forecast indicate a significant expansion driven by increasing demand for effective treatments. The industry expansion will be shaped by advancements in medical technology, changing regulatory landscapes, and shifting consumer behaviors, with key forces including technology shifts, regulations, and consumer behavior driving the market forward.

Loading chart…

The Night Blindness Treatment market is expected to grow at a CAGR of 7.5% from 2026 to 2033, driven by macro drivers such as an increasing prevalence of night blindness and advancements in treatment options. The largest region in the Night Blindness Treatment market is North America, while the fastest-growing region is Asia-Pacific. Key forces shaping the industry include competitive intensity and supply-chain dynamics, in addition to technology shifts, regulations, and consumer behavior. As the market continues to evolve, strategic planners and business development teams must stay informed about the latest developments and trends to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	679.59 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Pfizer; GlaxoSmithKline; Johnson & Johnson Private Limited; Roche Holding AG; Abbott; Mylan; Teva Pharmaceuticals; Sanofi; Novartis; Bayer; Sun Pharmaceutical Industries; Aurobindo Pharma; Lupin pharma; Eli Lilly and Company; Sumitomo Dainippon Pharma; Leo Pharma; Bausch Health; AstraZeneca; Cipla
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Night Blindness Treatment market is poised for significant growth, driven by increasing awareness and advancements in treatment options. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Advancements in gene therapy and pharmacological interventions are expanding the Night Blindness Treatment market size, offering new hope for patients and driving growth through increased treatment options.

Government initiatives and non-profit organizations' efforts to improve awareness about night blindness are contributing to the growth forecast, as more people seek medical attention and treatment.

Restraints2 items

High costs associated with advanced treatments, such as gene therapy, are limiting access to care, thereby constraining the Night Blindness Treatment market and affecting its potential for rapid expansion.

The lack of standardized diagnostic criteria for night blindness hinders accurate prevalence studies, making it challenging to assess the true market potential and develop targeted interventions.

Opportunities2 items

Emerging markets in low- and middle-income countries present significant opportunities for growth, as these regions have limited access to current treatments and a high unmet need for Night Blindness Treatment.

Collaborations between pharmaceutical companies, research institutions, and patient advocacy groups can accelerate the development of innovative treatments, driving the Night Blindness Treatment market size and improving patient outcomes.

Challenges2 items

The Night Blindness Treatment market faces challenges from stringent regulatory requirements, which can delay the approval and commercialization of new treatments, affecting the growth forecast and limiting patient access to innovative therapies.

Managing the economic burden of night blindness, including the costs of treatment and lost productivity, is a significant challenge that requires a multifaceted approach involving healthcare providers, payers, and policy makers to ensure sustainable and equitable access to care.

Market Segmentation

Loading chart…

The Type segment in the Night Blindness Treatment market refers to the different approaches used to treat night blindness, including vitamin A supplements, surgery, and gene therapy. This segmentation is crucial in understanding the Night Blindness Treatment segmentation landscape, as each type has its own set of benefits and limitations. For instance, vitamin A supplements are a common treatment option, while gene therapy is a more recent and promising approach. Understanding the market size and growth prospects of each type is essential for businesses and investors looking to capitalize on the Night Blindness Treatment market.

The Application segment in the Night Blindness Treatment market is categorized based on the specific use cases of night blindness treatments, such as congenital night blindness, acquired night blindness, and age-related night blindness. This segmentation helps in identifying the most significant areas of application and the corresponding market opportunities. By analyzing the application segment, stakeholders can determine the most promising areas to invest in and develop targeted solutions to address the specific needs of each application area, ultimately contributing to the overall Night Blindness Treatment market size.

Night Blindness Treatment Segmentation Breakdown7 items

Type

/> Vitamin AD Drops

Vitamin AD Softgels

Vitamin A Capsule

Application

/> Clinic

Hospital

Regional Insights

Loading chart…

The Night Blindness Treatment market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the market share, and also the fastest-growing region, driven by increasing adoption of advanced treatments, government policies supporting healthcare infrastructure development, and significant investments in research and development. In North America, key drivers include a high prevalence of night blindness, well-established infrastructure, and a mature ecosystem. Europe is driven by demographics, with an aging population, and a strong focus on regional forecast and market research.

In Latin America, the Night Blindness Treatment market is driven by increasing awareness and improving access to healthcare services. The Middle East & Africa region is expected to grow steadily, driven by government initiatives to improve healthcare infrastructure and increase access to treatments. Overall, the regional forecast indicates a strong growth potential for the Night Blindness Treatment market, with each region presenting unique opportunities and challenges.

Competitive Landscape

The Night Blindness Treatment market is moderately consolidated, with a mix of global players and local companies competing on pricing, distribution, and product innovation. The Night Blindness Treatment competitive landscape is driven by key competitive levers such as regulatory approvals, certifications, and partnerships. Global players are focusing on expanding their product portfolio and strengthening their distribution networks, while local companies are leveraging their regional presence and cost advantages to compete.

Companies in the Night Blindness Treatment market are adopting various strategies to differentiate themselves, including mergers and acquisitions, partnerships, and investments in research and development. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies are focusing on technology, service model, and channel strength to differentiate themselves. Some companies are also exploring customization and cost advantages to gain a competitive edge.

Merck: regional expansion

Pfizer: innovation pipeline

GlaxoSmithKline: premium pricing

Johnson & Johnson Private Limited: local manufacturing

Roche Holding AG: vertical integration

Abbott: OEM tie-ups

Key Night Blindness Treatment Companies20 items

Merck

Pfizer

GlaxoSmithKline

Johnson & Johnson Private Limited

Roche Holding AG

Abbott

Mylan

Teva Pharmaceuticals

Sanofi

Novartis

Bayer

Sun Pharmaceutical Industries

Aurobindo Pharma

Lupin pharma

Eli Lilly and Company

Sumitomo Dainippon Pharma

Leo Pharma

Bausch Health

AstraZeneca

Cipla

Market Ecosystem

The Night Blindness Treatment ecosystem encompasses a complex network of stakeholders, from upstream technology providers and suppliers to midstream integrators and downstream channels, ultimately serving end users. This ecosystem creates and captures value through the development, manufacturing, and distribution of treatments, as well as the provision of related services. The boundaries of this ecosystem are defined by the interactions and interdependencies among these various participants, influencing how value flows through the system.

Raw material suppliers — providing essential components

OEMs / manufacturers — producing treatment devices

Technology providers — developing underlying technologies

System integrators / EPCs — integrating treatment systems

Distributors / channel partners — delivering products to market

Service providers / after-sales — offering support and maintenance

Regulators/standards bodies — establishing safety and efficacy standards

Within the Night Blindness Treatment ecosystem, control points are primarily held by regulators and standards bodies, as their approvals and guidelines significantly influence the adoption of treatments. Dependency risks arise from input constraints, such as the availability of raw materials, and from standards and approvals that must be met. Switching costs and partnerships can also impact the ecosystem, particularly in terms of interoperability requirements among different treatment systems. As the ecosystem differs by region due to varying regulatory environments and market demands, a comprehensive value chain analysis is necessary to understand these dynamics and how they shape the Night Blindness Treatment ecosystem.

Recent Industry Insights

The Night Blindness Treatment industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have led to the creation of innovative products, while mergers and acquisitions have resulted in expanded product portfolios. Notably, several companies have launched new products and technologies, including advanced gene therapies and implantable devices, to address the growing demand for effective night blindness treatments. Furthermore, regulatory changes have paved the way for increased investment in research and development, driving growth in the Night Blindness Treatment market.

Additionally, there has been a shift in consumer trends, with a growing awareness of night blindness and its treatment options. This has led to increased funding rounds and expansions by companies operating in the Night Blindness Treatment industry, enabling them to develop and commercialize new treatments. As a result, the Night Blindness Treatment market is poised for significant growth, driven by advancements in technology, changing consumer trends, and evolving regulatory landscapes.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Night Blindness Treatment market. The market attractiveness is moderate, driven by increasing awareness and advancements in treatment options. The competitive intensity is relatively high, with key players investing heavily in research and development. The long-term outlook for the Night Blindness Treatment market outlook is promising, with expected growth driven by innovative therapies and expanding patient populations.

The innovation landscape is rapidly evolving, with gene therapies and novel medications being developed to address the underlying causes of night blindness. However, the demand–supply balance is a concern, as the availability of effective treatments is limited in certain regions. Key risk factors include regulatory challenges, pricing pressures, and the potential for _side effects_ from new treatments. Overall, the Night Blindness Treatment market presents opportunities for growth, but stakeholders must navigate these challenges to capitalize on the emerging trends and technologies.

11 items

1. Executive Summary

2. Night Blindness Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Night Blindness Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Night Blindness Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Vitamin AD Drops

6.1.2. Vitamin AD Softgels

6.1.3. Vitamin A Capsule

6.2. Global Night Blindness Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Clinic

6.2.2. Hospital

6.3. Global Night Blindness Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Night Blindness Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Night Blindness Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Night Blindness Treatment Market Competition by Key Manufacturers

8.1. Global Night Blindness Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Night Blindness Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Johnson & Johnson Private Limited

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche Holding AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abbott

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Mylan

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Teva Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sanofi

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Novartis

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bayer

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sun Pharmaceutical Industries

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Aurobindo Pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lupin pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Eli Lilly and Company

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Sumitomo Dainippon Pharma

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Leo Pharma

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Bausch Health

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. AstraZeneca

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Cipla

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Night Blindness Treatment Market

Figure 4: Global Night Blindness Treatment Market: Drivers

Figure 5: Global Night Blindness Treatment Market: Challenges

Figure 6: Global Night Blindness Treatment Market: Trends

Figure 7: Global Night Blindness Treatment Market: Opportunity

Figure 8: Global Night Blindness Treatment Market: Restraint

Figure 9: Global Night Blindness Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Night Blindness Treatment Market Value (USD Million) By Region

Figure 15: Global Night Blindness Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Night Blindness Treatment Market Value (USD Million) By Region

Figure 23: Global Night Blindness Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Night Blindness Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Night Blindness Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Night Blindness Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Night Blindness Treatment Market Value (USD Million) By Region

Table 10: Global Night Blindness Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Night Blindness Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Night Blindness Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Night Blindness Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: GlaxoSmithKline Basic Information And Sales Area

Table 35: GlaxoSmithKline. Products Portfolio

Table 36: Johnson & Johnson Private Limited Basic Information And Sales Area

Table 37: Johnson & Johnson Private Limited. Products Portfolio

Table 38: Roche Holding AG Basic Information And Sales Area

Table 39: Roche Holding AG. Products Portfolio

Table 40: Abbott Basic Information And Sales Area

Table 41: Abbott. Products Portfolio

Table 42: Mylan Basic Information And Sales Area

Table 43: Mylan. Products Portfolio

Table 44: Teva Pharmaceuticals Basic Information And Sales Area

Table 45: Teva Pharmaceuticals. Products Portfolio

Table 46: Sanofi Basic Information And Sales Area

Table 47: Sanofi. Products Portfolio

Table 48: Novartis Basic Information And Sales Area

Table 49: Novartis. Products Portfolio

Table 50: Bayer Basic Information And Sales Area

Table 51: Bayer. Products Portfolio

Table 52: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 53: Sun Pharmaceutical Industries. Products Portfolio

Table 54: Aurobindo Pharma Basic Information And Sales Area

Table 55: Aurobindo Pharma. Products Portfolio

Table 56: Lupin pharma Basic Information And Sales Area

Table 57: Lupin pharma. Products Portfolio

Table 58: Eli Lilly and Company Basic Information And Sales Area

Table 59: Eli Lilly and Company. Products Portfolio

Table 60: Sumitomo Dainippon Pharma Basic Information And Sales Area

Table 61: Sumitomo Dainippon Pharma. Products Portfolio

Table 62: Leo Pharma Basic Information And Sales Area

Table 63: Leo Pharma. Products Portfolio

Table 64: Bausch Health Basic Information And Sales Area

Table 65: Bausch Health. Products Portfolio

Table 66: AstraZeneca Basic Information And Sales Area

Table 67: AstraZeneca. Products Portfolio

Table 68: Cipla Basic Information And Sales Area

Table 69: Cipla. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Type

Table 71: Global Market Share (%) By Type (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global Night Blindness Treatment Market Value (USD Million) By Region

Table 75: Global Night Blindness Treatment Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Type

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Type

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Type

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Night Blindness Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	679.59 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Pfizer; GlaxoSmithKline; Johnson & Johnson Private Limited; Roche Holding AG; Abbott; Mylan; Teva Pharmaceuticals; Sanofi; Novartis; Bayer; Sun Pharmaceutical Industries; Aurobindo Pharma; Lupin pharma; Eli Lilly and Company; Sumitomo Dainippon Pharma; Leo Pharma; Bausch Health; AstraZeneca; Cipla
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options